Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.94 AUD | +2.54% | +4.84% | -6.62% |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 1,649 | 1,267 | 1,517 | 733.7 | 883.5 | 730.1 | - | - |
Enterprise Value (EV) 1 | 1,595 | 1,201 | 1,434 | 612.2 | 726.6 | 543.3 | 510.6 | 472.2 |
P/E ratio | 92 x | 77.7 x | 63.4 x | 36.8 x | 30.3 x | 21.3 x | 19.7 x | 17.2 x |
Yield | 0.07% | 0.1% | 0.08% | 0.27% | 0.28% | 0.46% | 0.51% | 0.63% |
Capitalization / Revenue | 53.1 x | 38.9 x | 31.6 x | 11.2 x | 11.3 x | 8.16 x | 7.4 x | 6.48 x |
EV / Revenue | 51.4 x | 36.9 x | 29.9 x | 9.32 x | 9.28 x | 6.07 x | 5.18 x | 4.19 x |
EV / EBITDA | 90.4 x | 92.2 x | 55 x | 16.4 x | 19.5 x | 12.4 x | 10.4 x | 8.34 x |
EV / FCF | 87.6 x | 90.3 x | 77.9 x | 15.5 x | 20.2 x | 15 x | 12.6 x | 9.62 x |
FCF Yield | 1.14% | 1.11% | 1.28% | 6.44% | 4.94% | 6.65% | 7.94% | 10.4% |
Price to Book | - | - | 15.4 x | 5.84 x | 5.37 x | 3.85 x | 3.31 x | 2.87 x |
Nbr of stocks (in thousands) | 48,961 | 49,410 | 49,410 | 49,410 | 49,410 | 50,108 | - | - |
Reference price 2 | 33.68 | 25.65 | 30.70 | 14.85 | 17.88 | 14.57 | 14.57 | 14.57 |
Announcement Date | 8/28/19 | 8/26/20 | 8/26/21 | 8/30/22 | 8/29/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 31.05 | 32.56 | 47.98 | 65.72 | 78.32 | 89.47 | 98.61 | 112.7 |
EBITDA 1 | 17.64 | 13.03 | 26.1 | 37.44 | 37.2 | 43.78 | 49.01 | 56.6 |
EBIT 1 | 17.55 | 12.6 | 25.24 | 36.68 | 36.41 | 42.75 | 47.55 | 55.24 |
Operating Margin | 56.53% | 38.69% | 52.61% | 55.82% | 46.49% | 47.78% | 48.22% | 49.04% |
Earnings before Tax (EBT) 1 | 18.11 | 13.14 | 25.71 | 34.32 | 45.58 | 50.58 | 54.68 | 59.58 |
Net income 1 | 18.13 | 16.65 | 24.73 | 20.88 | 30.6 | 34.71 | 37.47 | 42.84 |
Net margin | 58.41% | 51.12% | 51.54% | 31.77% | 39.08% | 38.8% | 38% | 38.02% |
EPS 2 | 0.3660 | 0.3300 | 0.4840 | 0.4030 | 0.5910 | 0.6853 | 0.7411 | 0.8475 |
Free Cash Flow 1 | 18.2 | 13.3 | 18.41 | 39.44 | 35.88 | 36.13 | 40.57 | 49.07 |
FCF margin | 58.61% | 40.84% | 38.37% | 60.01% | 45.82% | 40.39% | 41.14% | 43.55% |
FCF Conversion (EBITDA) | 103.16% | 102.09% | 70.53% | 105.33% | 96.45% | 82.53% | 82.78% | 86.7% |
FCF Conversion (Net income) | 100.35% | 79.89% | 74.44% | 188.89% | 117.25% | 104.1% | 108.25% | 114.54% |
Dividend per Share 2 | 0.0250 | 0.0250 | 0.0250 | 0.0400 | 0.0500 | 0.0675 | 0.0747 | 0.0914 |
Announcement Date | 8/28/19 | 8/26/20 | 8/26/21 | 8/30/22 | 8/29/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 13.63 | 34.34 | - | 41.09 | - | 48.97 | 32.26 | 53.9 |
EBITDA 1 | 5.613 | 20.49 | 9.847 | 27.71 | 14.91 | 22.3 | 13.74 | 33.3 |
EBIT 1 | 5.613 | 19.62 | 9.455 | 27.35 | 14.53 | 21.88 | 13.16 | 33.3 |
Operating Margin | 41.17% | 57.14% | - | 66.56% | - | 44.69% | 40.8% | 61.78% |
Earnings before Tax (EBT) 1 | 5.811 | 19.9 | 8.726 | 25.6 | 14.6 | 30.98 | 14.81 | 37.3 |
Net income 1 | 6.487 | 18.24 | 5.87 | 15.01 | 11.39 | 19.22 | 10.94 | 24.9 |
Net margin | 47.58% | 53.11% | - | 36.52% | - | 39.25% | 33.9% | 46.2% |
EPS 2 | 0.1270 | 0.3570 | 0.1140 | 0.2890 | 0.2200 | 0.3710 | 0.2120 | 0.4930 |
Dividend per Share 2 | - | 0.0250 | - | 0.0400 | - | 0.0500 | - | 0.0700 |
Announcement Date | 2/23/21 | 8/26/21 | 2/22/22 | 8/30/22 | 2/23/23 | 8/29/23 | 2/21/24 | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 54.3 | 66.7 | 82.7 | 122 | 157 | 187 | 219 | 258 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 18.2 | 13.3 | 18.4 | 39.4 | 35.9 | 36.1 | 40.6 | 49.1 |
ROE (net income / shareholders' equity) | 32% | - | 28.7% | 18.6% | 19% | 18.8% | 17.4% | 17.3% |
ROA (Net income/ Total Assets) | 34.5% | 23.1% | 26% | 16.5% | 18.1% | 15.4% | 14.6% | 13.9% |
Assets 1 | 52.62 | 71.94 | 95.05 | 126.3 | 168.8 | 225.7 | 256.6 | 308.6 |
Book Value Per Share 2 | - | - | 2.000 | 2.540 | 3.330 | 3.790 | 4.400 | 5.070 |
Cash Flow per Share 2 | 0.3700 | 0.2800 | 0.3800 | 0.7700 | 0.7100 | 0.8300 | 0.8400 | 0.9800 |
Capex 1 | 0.26 | 0.89 | 0.85 | 0.43 | 1.03 | 6.08 | 2.73 | 1.53 |
Capex / Sales | 0.83% | 2.73% | 1.78% | 0.66% | 1.31% | 6.79% | 2.77% | 1.36% |
Announcement Date | 8/28/19 | 8/26/20 | 8/26/21 | 8/30/22 | 8/29/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.44% | 476M | |
-4.40% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- CUV Stock
- Financials Clinuvel Pharmaceuticals Limited